{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-021614","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.957433+00:00","generated_at":"2026-06-24T02:56:30.137148+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lantern Pharma Q2 net loss $4.5M; launches Phase 2 Harmonic trial for LP-300 in never-smoker NSCLC","bullets":["Net loss of $4.5M ($0.41 per share) vs $2.3M ($0.21) in Q2 2021; R&D spend increased to $3.0M from $1.2M.","Cash, cash equivalents, and marketable securities $62.2M as of June 30, 2022, down from $79.6M a year ago; cash runway into 2025.","Phase 2 Harmonic trial for LP-300 launched; enrollment begins Q3 2022; initial results expected Q4 2023.","INDs for LP-184 and LP-284 planned for early 2023; Phase 1 trials for LP-184 (CNS + solid tumors) and LP-284 (NHL) anticipated in H1 2023.","RADR platform now exceeds 21 billion data points; Dr. Maria Maccecchini elected to board of directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-021614","json":"https://secwatch.observer/filing/0001493152-22-021614.json","markdown":"https://secwatch.observer/filing/0001493152-22-021614.md","text":"https://secwatch.observer/filing/0001493152-22-021614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315222021614/0001493152-22-021614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315222021614/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:56:30.137148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}